1) Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
DOI: 10.3322/caac.21834
2) Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin . 2020;70:145–164
DOI: 10.3322/caac.21601
3) Las cifras del cáncer en España 2025. Depósito Legal: M-2567-2025. ISBN: 978-84-09-69154-8 © 2025. Sociedad Española de Oncología Médica (SEOM). Disponible en: https://seom.org/images/LAS_CIFRAS_DMC2025.pdf
4) Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw . 2022;20:1139–1167 .
DOI: 10.6004/jnccn.2022.0051
5) Gandini A, Sciallero S, Martelli V, Pirrone C, Puglisi S, Cremante M, et al. A Comprehensive Approach to Neoadjuvant Treatment of Locally Advanced Rectal Cancer. Cancers (Basel). 2025 Jan 20;17(2):330.
DOI: 10.3390/cancers17020330
6) Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment. Eur J Cancer. 2022;175:136-157.
DOI: 10.1016/j.ejca.2022.07.020
7) André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite- instability-high advanced colorectal cancer. N Engl J Med. 2020;383 (23):2207-2218.
DOI: 10.1056/NEJMoa2017699
8) Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
DOI: 10.1056/NEJMoa1500596
9) Zhu J, Lian J, Xu B, Pang X, Ji S, Zhao Y, Lu H. Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions? Front Immunol. 2023 Mar 6;14:1120684.
DOI: 10.3389/fimmu.2023.1120684
10) Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1;38(1):1-10.
DOI: 10.1200/JCO.19.02105
11) Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, et al. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clin Cancer Res. 2020 Jul 1;26(13):3271-3279.
DOI: 10.1158/1078-0432.CCR-19-3728
12) Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022 May;23(5):659-670
DOI: 10.1016/S1470-2045(22)00197-8
13) Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med. 2020 Apr;26(4):475-484.
DOI: 10.1038/s41591-020-0829-0
14) Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006 Sep 29;313(5795):1960-4.
DOI: 10.1126/science.1129139
15) Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128-2139.
16) Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta. 2013 Dec;1836(2):187-96.
DOI: 10.1016/j.bbcan.2013.05.003
17) Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol. 2019 Aug;234(10):16824-16837.
DOI: 10.1002/jcp.28358
18) Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002 Aug;8(8):793-800.
DOI: 10.1038/nm730
19) Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 Jan 10;40(2):161-170.
DOI: 10.1200/JCO.21.01015
20) Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ, Teng MW. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016 Dec;6(12):1382-1399
DOI: 10.1158/2159-8290.CD-16-0577
21) Airoldi M, Roselló S, Tarazona N, Huerta M, Pérez-Santiago L, Fleitas T, et al. Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life. Cancer Treat Rev. 2025 Nov;140:103015.
DOI: 10.1016/j.ctrv.2025.103015
22) Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022 Jun 23;386(25):2363-2376.
DOI: 10.1056/NEJMoa2201445
23) Cercek, A.; Sinopoli, J.C.; Shia, J.;Weiss, J.A.; Temple, L.; Smith, J.J.; Saltz, L.B.;Widmar, M.; Fumo, G.; Aparo, S.; et al. Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. J. Clin. Oncol. 2024, 42 (Suppl. S17), LBA3512
DOI: 10.1200/JCO.2024.42.17_suppl.LBA3512
24) Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, et al. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023 May;8(5):422-431.
DOI: 10.1016/S2468-1253(22)00439-3
25) Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. (2022) 7:38–48.
26) Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol. 2023;41(12):2181-2190.
DOI: 10.1200/JCO.22.01351
27) Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, et al. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. Clin Cancer Res. (2022) 28:1136–46.
DOI: 10.1158/1078-0432.CCR-21-3213
28) Cui HX, Yang XQ, Zhao GY, Wang FJ, Liu X. The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review. Front Immunol. 2025 May 1;16:1540751.
DOI: 10.3389/fimmu.2025.1540751
29) Luo Z, Wang D, Wang Z, Zhao H, Xiang R. Is neoadjuvant immunotherapy feasible for patients with dMMR/MSI-H locally advanced colorectal cancer? a retrospective study. Front Immunol. 2025 Aug 12;16:1645412.
DOI: 10.3389/fimmu.2025.1645412
30) Bahadoer RR, Dijkstra EA, Van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 2021 Jan;22(1):29–42.
31) Conroy T, Etienne PL, Rio E, Evesque L, Mesgouez-Nebout N, Vendrely V, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol 2023.
DOI: 10.1200/JCO.2023.41.17_suppl.LBA3504
32) Ciseł _B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 ×5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2019 Aug;30(8):1298–303.
DOI: 10.1093/annonc/mdz186
33) ]Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 2022 May 20;40(15):1681–92.
34) Turri G, Ostuzzi G, Vita G, Barresi V, Scarpa A, Milella M, et al. Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. 2024 Jun 3;7(6):e2414702.
DOI: 10.1001/jamanetworkopen.2024.14702
35) Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 2022 Aug 10;40(23):2546–56.
36) Conroy T, Bosset JF, Etienne PL, Rio E, François ´E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER- PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021 May;22(5):702–15.
DOI: 10.1016/S1470-2045(21)00079-6
37) Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus pre-operative chemoradiotherapy, TME, and optional adjuvant chemo-therapy in locally advanced rectal cancer (RAPIDO): a randomised, open- label, phase 3 trial. Lancet Oncol. 2021;22:29–42.
DOI: 10.1016/S1470-2045(20)30555-6
38) Jin J, Tang Y, Hu C, Jiang L, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short- term radiotherapy plus chemotherapy versus long- term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681–92.
DOI: 10.1200/JCO.21.01667
39) Xiao Y, Xue H, Zhong G, Zhou W, Xu L, Du X, Zhang G, Wu B, Lin G, Qiu H. [Predictive value of preoperative imaging and postoperative pathology on clinical complete response after neoadjuvant chemoradiation for locally advanced rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015 May;18(5):474-7.
40) Liu YX, Yang XR, Peng LQ, Li ZH. A management of patients achieving clinical complete response after neoadjuvant therapy and perspectives: on locally advanced rectal cancer. Front Oncol. 2025 Jan 8;14:1450994.
DOI: 10.3389/fonc.2024.1450994
41) Cerdán-Santacruz C, Vailati BB, São Julião GP, Habr-Gama A, Perez RO. Local tumor regrowth after clinical complete response following neoadjuvant therapy for rectal cancer: what happens when organ preservation falls short. Tech Coloproctol. 2023 Jan;27(1):1-9.
DOI: 10.1007/s10151-022-02654-5
42) Moreno CC, Sullivan PS, Mittal PK. MRI Evaluation of Rectal Cancer: Staging and Restaging. Curr Probl Diagn Radiol. 2017 May-Jun;46(3):234-241.
DOI: 10.1067/j.cpradiol.2016.11.011
43) De Felice F, Magnante AL, Musio D, Ciolina M, De Cecco CN, Rengo M, et al. Diffusion-weighted magnetic resonance imaging in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Eur J Surg Oncol. 2017 Jul;43(7):1324-1329.
DOI: 10.1016/j.ejso.2017.03.010
44) Shayesteh SP, Alikhassi A, Fard Esfahani A, Miraie M, Geramifar P, Bitarafan-Rajabi A, Haddad P. Neo-adjuvant chemoradiotherapy response prediction using MRI based ensemble learning method in rectal cancer patients. Phys Med. 2019 Jun;62:111-119.
DOI: 10.1016/j.ejmp.2019.03.013
45) He J, Wang SX, Liu P. Machine learning in predicting pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer using MRI: a systematic review and meta-analysis. Br J Radiol. 2024 Jun 18;97(1159):1243-1254.
DOI: 10.1093/bjr/tqae098
46) Zhai M, Lin Z, Wang H, Yang J, Li M, Li X, Zhang L, Zhang T. Can rectal MRI and endorectal ultrasound accurately predict the complete response to neoadjuvant immunotherapy for rectal cancer? Gastroenterol Rep (Oxf). 2024 Apr 8;12:goae027.
DOI: 10.1093/gastro/goae027
47) Wang Y, Yang L, Bao H, Fan X, Xia F, Wan J, Shen L, Guan Y, Bao H, Wu X, Xu Y, Shao Y, Sun Y, Tong T, Li X, Xu Y, Cai S, Zhu J, Zhang Z. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Med. 2021 Aug 31;18(8):e1003741.
DOI: 10.1371/journal.pmed.1003741
48) Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024 Nov;30(11):3272-3283.
DOI: 10.1038/s41591-024-03254-6
49) van Rees JM, Wullaert L, Grüter AAJ, Derraze Y, Tanis PJ, Verheul HMW, et al. Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses. Front Oncol. 2023 Jan 30;13:1083285.
DOI: 10.3389/fonc.2023.1083285
50) Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, et al. Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clin Cancer Res. 2021 May 15;27(10):2890-2898.
DOI: 10.1158/1078-0432.CCR-20-4769
51) Amatu A, Zampino MG, Bergamo F, Mosconi S, Sibio D, Gerardi M, et al. 509O Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): first results of NO-CUT trial. Ann Oncol 2024 Sep;35:S431–2.
DOI: 10.1016/j.annonc.2024.08.578
52) Liu J, Liu K, Cao F, Hu P, Bi F, Liu S, et al. MRI-based radiomic nomogram for predicting disease-free survival in patients with locally advanced rectal cancer. Abdom Radiol (NY). 2025 Jun;50(6):2388-2400.
DOI: 10.1007/s00261-024-04710-0
53) Boldrini L, Chiloiro G, Di Franco S, Romano A, Smiljanic L, Tran EH, et al. MOREOVER: multiomics MR-guided radiotherapy optimization in locally advanced rectal cancer. Radiat Oncol. 2024 Jul 25;19(1):94.
DOI: 10.1186/s13014-024-02492-9
Número de descargas:
94
Número de visitas:
6
Citas:
0
